Rocklatan costs roughly $360 to $390 for a single 2.5 mL bottle without insurance, making it one of the priciest daily eye drops on the market. By comparison, generic latanoprost, one of its two active ingredients, runs about $11 to $13 for the same size bottle. That enormous gap comes down to a combination of patent protection, a novel drug class with almost no competition, and the absence of any generic alternative.
What Makes Rocklatan Different
Rocklatan combines two pressure-lowering ingredients in a single drop: latanoprost, a decades-old glaucoma staple that increases fluid drainage from the eye, and netarsudil, a newer compound that works through a completely different pathway. Netarsudil belongs to a drug class called rho kinase inhibitors, which lower eye pressure by relaxing the tissue in the eye’s main drainage channel and reducing the amount of fluid the eye produces. Only two rho kinase inhibitors exist worldwide, and netarsudil is the only one approved in the United States.
The FDA approved Rocklatan in 2019 specifically because it lowers intraocular pressure more effectively than either ingredient alone. For patients whose glaucoma isn’t controlled by a single medication, Rocklatan offers the convenience of one drop instead of two separate bottles on different schedules. That clinical edge, combined with its novelty, gives the manufacturer significant pricing power.
Patent Protection Until 2034
The single biggest reason Rocklatan stays expensive is its patent portfolio. FDA records show the last qualifying patent on Rocklatan doesn’t expire until March 2034. Until that date, no other company can legally manufacture a generic version. Patents on combination drugs tend to extend further than those on their individual ingredients because the specific formulation itself is protected, even when one component (latanoprost) has long been available generically.
This means patients face at least another decade of brand-only pricing. Generic competition is typically what drives drug prices down by 80% or more, and without it, the manufacturer has no market pressure to lower the cost.
Almost Zero Competition
Most drug categories have several brand-name options competing for the same patients, which helps keep prices in check. Rocklatan’s situation is unusual. The rho kinase inhibitor class has only two approved drugs globally: netarsudil (marketed in the U.S.) and ripasudil (available in Japan). No other combination product pairs a rho kinase inhibitor with latanoprost. That leaves Rocklatan essentially alone in its niche, with no therapeutic equivalent a doctor could substitute.
When a drug has no close competitors, insurers have less leverage to negotiate discounts, and the manufacturer can set prices based on clinical value rather than market competition. Doctors who want this specific mechanism of action for a patient have nowhere else to turn.
Insurance Coverage Varies Widely
Whether you actually pay the full retail price depends heavily on your insurance plan. Many commercial insurers and Medicare Part D plans do cover Rocklatan, but it’s frequently placed on higher formulary tiers, meaning larger copays or coinsurance. Some plans require prior authorization or step therapy, which means you have to try cheaper alternatives first and show they didn’t work before the insurer will approve Rocklatan.
For patients without insurance or whose plans don’t cover it, the out-of-pocket cost hovers around $390 per bottle. A single bottle typically lasts about one month when used as directed (one drop per eye, once daily), putting the annual cost near $4,700 at retail price.
Ways to Reduce the Cost
If your doctor has prescribed Rocklatan and the price is a barrier, a few options may help. The manufacturer, Astellas (which acquired the drug’s original developer), has offered copay assistance programs for commercially insured patients. Eligibility and savings amounts change periodically, so checking the manufacturer’s website or asking your pharmacy is the most reliable way to get current terms.
Prescription discount programs and pharmacy coupons through services like GoodRx or RxSaver sometimes bring the price down modestly, though the savings on a $390 drug are often less dramatic than on more widely available medications. If cost is prohibitive, the most common clinical workaround is using the two ingredients separately: generic latanoprost at roughly $12 plus a separate bottle of brand-name netarsudil. This doesn’t necessarily save money overall since netarsudil alone is also expensive, but it may be covered differently by certain insurance plans.
For some patients, the conversation with their eye doctor shifts to whether a different combination of generic glaucoma drugs, working through other mechanisms, can achieve adequate pressure control at a fraction of the cost. That trade-off between maximum effectiveness and affordability is one worth having openly with your provider.
Why the Price Is Unlikely to Drop Soon
Drug pricing in the U.S. is shaped by patent exclusivity, competition, and insurer negotiations. Rocklatan hits the trifecta of factors that keep prices high: strong patent protection extending to 2034, a first-in-class mechanism with no generic pathway available, and minimal direct competition. Until either a generic version reaches the market or a competing rho kinase inhibitor combination is approved, Rocklatan’s price will likely remain in the same range it occupies today.